CytomX Q2 2026: Cash Runway to H2 2028, Varseta-M Registrational Study Planned for 1H 2027

summarizeSummary

CytomX Therapeutics reported Q2 2026 financial results and provided a business update, highlighting a cash runway to at least H2 2028 and advancement of its lead ADC program, Varseta-M, toward a registrational study in colorectal cancer.

check_boxKey Events · Earnings and Guidance · CTMX

• Cash Runway Extended to H2 2028

  Ended Q2 2026 with $330.3 million in cash, cash equivalents, and investments, plus $37 million received in July from Regeneron, funding operations to at least the second half of 2028.

• Varseta-M Registrational Study Planned

  Phase 1 enrollment complete at 113 patients; a data update is expected by end of 2026, with FDA interactions planned and a registrational study in CRC targeted for 1H 2027.

• Varseta-M Expansion into New Indications

  Phase 1 monotherapy expansion cohorts in gastric/GEJ, EpCAM-selected PDAC, and EpCAM-selected BTC are initiating in Q3 2026, broadening the program's pan-tumor potential.

• CX-801 Combo Advances in Melanoma

  CX-801 in combination with KEYTRUDA has cleared the third dose level in Phase 1; initial clinical data expected in 1H 2027.

auto_awesomeAnalysis · CTMX · Life Sciences

CytomX reported Q2 2026 results with a net loss of $20.7 million on revenue of $1.4 million, but the key takeaway is the strengthened cash position — $330.3 million as of June 30, plus $37 million received in July from Regeneron — extending runway to at least the second half of 2028. The Varseta-M program is advancing toward a registrational study in colorectal cancer, with a Phase 1 data update expected by year-end and FDA interactions planned. Expansion into additional gastrointestinal cancers is starting this quarter. The combination of a solid cash runway and a clear path to a pivotal trial for the lead asset makes this a notable update for a $734 million market cap company.